How should the DXA findings and FRAX risk be interpreted and managed in a 65-year-old patient with osteoporosis on alendronate 70 mg weekly?

DXA Interpretation and Management Recommendation

This patient requires continued alendronate therapy with close monitoring, not a bisphosphonate holiday, due to persistently very high fracture risk despite current treatment. 1

Critical DXA Findings Analysis

Your patient presents with concerning mixed results that warrant immediate attention:

Worrisome Findings:

• Left femoral neck T-score: -3.0 (osteoporosis range)
• Significant 6.4% BMD decrease at femoral neck from previous scan
• FRAX scores remain extremely elevated: 41.9% 10-year major osteoporotic fracture risk and 8.3% hip fracture risk
• Left total hip T-score: -2.7 (osteoporosis)

Positive Finding:

• Lumbar spine improved 11.2% to T-score -1.7 (now osteopenia range)

Why This Patient Should NOT Take a Bisphosphonate Holiday

The Endocrine Society 2019 guidelines are explicit: after 3-5 years of bisphosphonate therapy, only patients at low-to-moderate fracture risk should be considered for a drug holiday, while those at high risk should continue therapy. 1

Your patient definitively remains at very high fracture risk based on:

1. FRAX major osteoporotic fracture risk of 41.9% (treatment threshold is ≥20%) 1
2. Hip fracture risk of 8.3% (treatment threshold is ≥3%) 1
3. Worsening femoral neck BMD despite treatment—a 6.4% decline is clinically significant
4. Persistent osteoporosis at hip sites (T-scores -2.7 to -3.0)

The Femoral Neck Decline is the Red Flag

The significant BMD loss at the femoral neck while on alendronate suggests one of several problems:

• Poor medication adherence (most common—alendronate's complex dosing requirements make this likely) 2
• Malabsorption of oral bisphosphonate
• Secondary causes of bone loss not yet identified
• Inadequate treatment response requiring therapy escalation

Immediate Action Plan

1. Assess Medication Adherence First

Directly question the patient about:

• Taking alendronate on empty stomach with full glass of plain water only
• Remaining upright for 30-60 minutes after dosing
• Waiting 30+ minutes before eating, drinking anything besides water, or taking other medications
• Missing doses or taking "drug holidays" on their own

Studies show only 16% of patients achieve optimal adherence to alendronate's seven dosing instructions. 2 Given the femoral neck decline, non-adherence is the most likely explanation.

2. Evaluate for Secondary Causes

Check for conditions causing treatment failure:

• Vitamin D level (target ≥30 ng/mL)
• Serum calcium and phosphate
• Thyroid function (hyperthyroidism accelerates bone loss)
• Celiac disease screening if any GI symptoms
• 24-hour urine calcium (to exclude hypercalciuria)
• Serum protein electrophoresis if age >65 with unexplained bone loss

3. Consider Bone Turnover Marker Testing

The Endocrine Society suggests monitoring serum CTX or P1NP to identify poor response or non-adherence. 1 A lack of suppression of bone turnover markers on alendronate would confirm inadequate treatment effect.

4. Treatment Modification Strategy

If adherence is the issue:

• Switch to zoledronic acid 5 mg IV annually (eliminates daily compliance burden and GI absorption issues) 1, 3
• Zoledronic acid shows 42% hip fracture reduction and 56% vertebral fracture reduction 1

If adherence is confirmed good:

• Consider switching to denosumab 60 mg subcutaneously every 6 months (no GI issues, no renal dose adjustment needed) 3
• Or escalate to anabolic therapy (teriparatide, abaloparatide, or romosozumab) given very high fracture risk and treatment failure 3

The AACE 2020 guidelines specifically recommend anabolic agents for patients at very high fracture risk, which includes those with very low T-scores or multiple risk factors. 3

Monitoring Plan Going Forward

Reassess BMD in 1-2 years (not sooner—annual DXA is maximum frequency). 1, 4 For patients on osteoporosis therapy at high/very high risk, guidelines strongly recommend fracture risk reassessment every 1-2 years. 4, 5

Expected BMD changes with proper treatment:

• Alendronate: +5% total hip, +7% lumbar spine at 2 years 1
• Zoledronic acid: +4% total hip, +7% lumbar spine at 2 years 1
• Denosumab: +5% total hip, +8% lumbar spine at 2 years 1

Critical Pitfall to Avoid

Do not discontinue bisphosphonate therapy based solely on lumbar spine improvement. The hip BMD is the most important predictor of hip fracture risk, and your patient's hip sites are worsening. The lumbar spine improvement may reflect degenerative changes (facet arthritis, osteophytes, aortic calcification) artificially elevating the BMD reading—a common phenomenon in older adults. 6

The lowest T-score determines treatment decisions, and at -3.0 (femoral neck), this patient has severe osteoporosis requiring continued aggressive therapy. 6

Calcium and Vitamin D Optimization

Ensure adequate intake regardless of pharmacologic choice:

• Calcium: 1,200 mg daily (dietary plus supplement)
• Vitamin D: 800-1,000 IU daily minimum, titrated to maintain serum 25(OH)D ≥30 ng/mL 1, 4

Bottom Line for Your Patient

Continue osteoporosis pharmacotherapy—do not initiate a drug holiday. The worsening femoral neck BMD and persistently very high FRAX scores (both >4x treatment thresholds) mandate ongoing treatment. Address adherence barriers first, then consider switching to parenteral therapy (IV zoledronic acid or subcutaneous denosumab) or escalating to anabolic therapy if adherence is confirmed adequate. The 11% lumbar spine improvement is encouraging but insufficient to offset the concerning hip deterioration in this very-high-risk patient.